Cleared Traditional

K062530 - TRIAGE PROTEIN C TEST

K062530 is the FDA 510(k) clearance for TRIAGE PROTEIN C TEST by Biosite Incorporated. It is a Class 2 Hematology device (product code GGP) cleared through the Traditional 510(k) pathway after a 153-day FDA review.

K062530 · Biosite Incorporated · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2007
Decision
153d
Days
Class 2
Risk

K062530 is an FDA 510(k) clearance for the TRIAGE PROTEIN C TEST. Classified as Test, Qualitative And Quantitative Factor Deficiency (product code GGP), Class II - Special Controls.

Submitted by Biosite Incorporated (San Diego, US). The FDA issued a Cleared decision on January 29, 2007 after a review of 153 days - an extended review cycle.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all Biosite Incorporated devices

Submission Details

510(k) Number K062530 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 29, 2006
Decision Date January 29, 2007
Days to Decision 153 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
40d slower than avg
Panel avg: 113d · This submission: 153d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GGP Test, Qualitative And Quantitative Factor Deficiency
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGP Test, Qualitative And Quantitative Factor Deficiency

All 126
Devices cleared under the same product code (GGP) and FDA review panel - the closest regulatory comparables to K062530.
HEMOSIL VON WILLEBRAND ACTIVITY ASSAY
K133005 · Instrumentation Laboratory CO · Mar 2014
HEMOSIL PROTEIN S ACTIVITY ASSAY
K102164 · Instrumentation Laboratory CO · Mar 2011
HEMOSIL PROCLOT
K070635 · Instrumentation Laboratory CO · Mar 2007
HEMOSIL PROTEIN C
K062430 · Instrumentation Laboratory CO · Sep 2006
HEMOSIL PROS
K053499 · Instrumentation Laboratory CO · Jan 2006
COATEST SP FVIII
K042576 · Instrumentation Laboratory CO · Dec 2004